Roche regulatory update

The pharma company filed an NDA with the FDA for Invirase (saquinavir) protease inhibitor to treat advanced HIV (CD4 counts £300) in combination with HIVID and/or AZT, and as a monotherapy in patients unable to tolerate other therapies.

Separately, the U.S. Patent and Trademark Office declared an interference on the patent claims of Hoffmann-La Roche (Nutley, N.J.) and Memorial Sloan Kettering Cancer Center over homogeneous human Interleukin-2. The New York center received U.S. Patent No. 4,925,919 covering the cytokine in May 1990. ...